These results suggest that Pra-B can act as an antimetastatic agent through suppressing CTSC and CTSV expression as well as migration and invasion through downregulating the EGFR–MEK–ERK signaling cascade in RCC cells (Figure 6). This evidence concerns the gene MAP2K7 and renal cell carcinoma.